All In Biotech

Free tool

FAERS Monitor: Zyclara

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022483 or its brand name (Zyclara, Imiquimod). Reports on generic versions are filed under their own applications.

Reports

2,334

Serious

1,287

55% of reports

Hospitalization

331

Death reported

73

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use265
  • erythema185
  • fatigue181
  • product use in unapproved indication177
  • drug ineffective171
  • pain137
  • nausea114
  • influenza like illness103
  • application site erythema102
  • headache95
  • pruritus88
  • pyrexia85
  • scab77
  • application site pain75
  • malaise75

Reports by year received

View as table
YearReports
20044
20052
20069
20071
20087
200911
201015
201155
201264
201369
201464
2015119
2016198
2017220
2018216
2019185
2020211
2021110
2022166
2023163
2024117
2025180
2026148

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,825 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
scabSignal7761.349.14,476
application site erythemaSignal10235.229.13,347
application site painSignal7530.824.62,127
influenza like illnessSignal10311.39.3958
erythemaSignal1858.17.11,158
product use in unapproved indicationSignal1776.45.6817
off label useSignal2652.72.4301
pyrexiaSignal852.21.856
fatigueSignal1812.11.8106
pruritusSignal882.11.748
painSignal1372.01.771
malaise751.51.214
headache951.41.19
nausea1141.31.18
drug ineffective1711.21.04

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.